Compare GoPro Inc (GPRO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs State Street SPDR S&P Biotech ETF — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 41.5× GoPro Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GPRO | XBI | |
|---|---|---|
Market Cap | $243.50M | $10.11B |
Volume | 11,527,160 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.31 | $169.55 |
52-Week Low | $0.58 | $104.99 |
Typical Hold Time | 45 Days | 38 Days |
Enterprise Value | $302.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro trades at $1.18, down 3.28% on the day, with a bullish technical signal but weak fundamentals. Revenue has declined from $1.1B in 2022 to $652M in 2025, with consistent net losses and negative cash flow. Recent news highlights a proposed $1.14 per share merger with Starman Optical and a surge in stock price driven by influencer investment and AI pivot speculation.
The outlook is highly speculative, driven by merger prospects rather than operational improvement. Investment opportunity hinges on the merger completion offering a near-term exit at a premium, but risks include shareholder litigation over deal fairness, continued cash burn, and competitive pressures from smartphones eroding the core business.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
